ClinicalTrials.Veeva

Menu
C

Clinical Science Institute | Santa Monica, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

PF-04965842
PF-06700841
Dupilumab
Apremilast
Rocatinlimab
Guselkumab
Amlitelimab
Lebrikizumab
Ixekizumab
LY3009104

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

23 of 90 total trials

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE)....

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: Litifilimab
Drug: Placebo

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-...

Enrolling
Moderate to Severe Atopic Dermatitis
Drug: Rezpegaldesleukin
Drug: Placebo

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 1...

Enrolling
Plaque Psoriasis
Drug: Apremilast

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

Enrolling
Plaque Psoriasis
Drug: Placebo
Drug: LY3972406

The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.

Enrolling
Plaque Psoriasis
Drug: Placebo
Drug: LY4100511

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and ge...

Enrolling
Palmoplantar Psoriasis
Genital Psoriasis
Drug: Placebo
Drug: Deucravacitinib

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent parti...

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a po...

Active, not recruiting
Psoriatic Plaque
Drug: KBL697

This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody re...

Enrolling
Dermatitis Atopic
Drug: Amlitelimab
Biological: Tdap vaccine

Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis

Active, not recruiting
Chronic Plaque Psoriasis
Moderate to Severe Nail Psoriasis
Drug: Placebo
Drug: Tildrakizumab

This is a single group, Phase 2/3, long-term extension study for treatment. The purpose of this study is to characterize the safety and efficacy of a...

Enrolling
Dermatitis Atopic
Drug: Oral corticosteroids
Drug: Amlitelimab

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have bee...

Active, not recruiting
Psoriasis
Drug: BMS-986165

A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with m...

Active, not recruiting
Discoid Lupus Erythematosus
Drug: Placebo/Daxdilimab
Drug: Daxdilimab

The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-...

Active, not recruiting
Scalp Psoriasis
Plaque Psoriasis
Drug: Placebo
Drug: Guselkumab

Trial sponsors

Pfizer logo
Amgen logo
Lilly logo
LEO Pharma logo
Janssen (J&J Innovative Medicine) logo
AnaptysBio logo
Bristol-Myers Squibb (BMS) logo
Nektar Therapeutics logo
Sanofi logo
AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems